Who is Baysient?
Baysient creates cloud-based software to facilitate individualized dosing of anti-inflammatory MAbs to improve outcomes in patients with inflammatory diseases like IBD. Baysient’s software utilizes a pioneering Compuceutical approach with Bayesian models, routine lab results and demographic information to allow physicians to individualize dosing to a specific target trough level.
Why Baysient?
How Does It Work?
Schedule a Demo
Interested in how iDose can improve your patient outcomes?
Diane R. Mould, PhD
Dr. Diane R. Mould, Chief Scientific Officer (CSO) of Baysient, discusses individual variability in infliximab excretion and elimination. The variations seen in the individual pharmacokinetics of biologics highlight the need for more prospective data to further support effective personalized dosing. By focusing on important, modifiable factors for regulating drug levels, we can improve the efficacy of inflammatory disease treatments in clinical settings.
Latest Blog Post
Mirikizumab and PK-Informed Therapeutic Drug Monitoring: Bringing Clarity to Individual Exposure
Mirikizumab is a first-in-class monoclonal antibody that targets the p19 subunit of interleukin-23. It is approved for moderate-to-severe active ulcerative colitis and, as of January 2025, Crohn's disease in adults, giving clinicians a newer option across the inflammatory bowel disease spectrum. As with any biologic,…
